Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 121.35M P/E - EPS this Y -253.80% Ern Qtrly Grth -
Income -25.72M Forward P/E -3.88 EPS next Y -8.70% 50D Avg Chg 13.00%
Sales 58.36M PEG - EPS past 5Y - 200D Avg Chg 71.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -19.00%
Recommedations 1.70 Quick Ratio 6.90 Shares Outstanding 91.06M 52W Low Chg 201.00%
Insider Own 5.03% ROA -10.88% Shares Float 79.98M Beta 2.84
Inst Own 47.80% ROE - Shares Shorted/Prior 10.80M/10.79M Price 2.17
Gross Margin 68.49% Profit Margin -44.07% Avg. Volume 642,427 Target Price 9.44
Oper. Margin 0.27% Earnings Date Nov 4 Volume 563,562 Change -3.12%
About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Aquestive Therapeutics, Inc. News
11/16/24 Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025?
11/12/24 Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
11/06/24 Aquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
11/06/24 Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...
11/04/24 Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
11/04/24 Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
11/04/24 Aquestive Therapeutics: Q3 Earnings Snapshot
11/04/24 Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
10/25/24 Aquestive Therapeutics’ Breakthrough in Allergy Treatment Study
10/25/24 Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting
10/24/24 Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
07:00 AM Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
09/30/24 Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
09/27/24 Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
09/09/24 Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
08/14/24 Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
08/08/24 Aquestive Therapeutics Second Quarter 2024 Earnings: Beats Expectations
08/06/24 Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
08/06/24 Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
08/06/24 Aquestive Therapeutics: Q2 Earnings Snapshot
AQST Chatroom

User Image TaZMaNiDEviL Posted - 50 minutes from now

$AQST 👀

User Image prototyper Posted - 8 minutes from now

$AQST Exactly where the offering was at 4.50. Tutes want their money back at 3X, 4X . Buying dips

User Image nomas Posted - 6 minutes from now

$AQST need the patience of Job with this thing . . . .

User Image TIG2 Posted - 22 minutes ago

$AQST At least spry is getting hammered with us ...

User Image Skinny__ Posted - 24 minutes ago

$AQST may need to just stop looking at this until 25

User Image Cardsharkiam Posted - 31 minutes ago

$AQST An early Xmas gift! Added 1800 more!

User Image LDstocks2023 Posted - 32 minutes ago

$AQST that is quite plumb !

User Image prototyper Posted - 35 minutes ago

$AQST URGH... SMH...

User Image RCaptain Posted - 37 minutes ago

$AQST Must be Thursday. Red today green tomorrow?

User Image LDstocks2023 Posted - 38 minutes ago

$AQST maybe one day we’ll get there 🥶🤷🏻‍♂️

User Image Outrageous Posted - 39 minutes ago

$AQST It’s been almost 4-5 weeks since AQST asked for the Pre-NDA meeting with regards to Anaphylm based on their PR back in October, 2024. From that PR: “Aquestive has requested a pre-NDA meeting with the FDA and expects to meet with the FDA in the fourth quarter of 2024. The Company remains on track to commence a pediatric study in subjects weighing 30 kgs and above in the fourth quarter 2024 and to submit a New Drug Application (NDA) to the FDA in the first quarter 2025. If approved by the FDA, Aquestive is poised to initiate a full product launch of Anaphylm in the first quarter of 2026.”

User Image drose0527 Posted - 46 minutes ago

$AQST 🤣🤣🤣 the games people play! Not sure why we continue to fall I would have thought this would be closer to 52 week high rather than floating at these levels. But WTF do I know! I guess we are always at the mercy of Wall Street and it’s constant manipulation

User Image Outrageous Posted - 1 hour ago

$AQST Coming Real Soon! Pediatric Study Completion, results of Pre NDA Meeting with the FDA. The shift in sentiment is about to explode to the positive IMHO.

User Image Outrageous Posted - 2 hours ago

$AQST AQST’s drug Sympazan as mentioned in Asserio’s Q3, 2024 Earnings call: “Looking at Sympazan, while this is a smaller asset, we believe that it has underpenetrated the market and there is room for growth. We also understand that Sympazan is especially responsive to key opinion leader awareness and support. I think I mentioned on the last call that we’re piloting and executing sales and marketing tactics designed to drive prescriber awareness and prescription growth in key markets. Although early, we have seen record demand levels in Sympazan prescriptions in July and August as a result of these activities. This is a product I liked from the beginning of my time at Assertio. It serves a specific unmet medical need, we have a broad coalition of growing support among patients, caregivers and providers and look to expand both awareness and use of Sympazan going forward.”

User Image ClearCities Posted - 11 hours ago

$AQST looks like Viatris is pilling up their cash on hand. Went from 1Bil to now 2Bil. They could rlly use that to buy aqst

User Image MateoYo Posted - 12 hours ago

$AQST No chatter, no mm manipulation. Just a small bio trying to bring a great product to market. Long and happily waiting for the organic sp increase over the next year...

User Image RCaptain Posted - 19 hours ago

$AQST You can tell what time of day it is by the price action. At least within an hour.

User Image RoyMunson69 Posted - 20 hours ago

$AQST Wow I killed it with one post. My power is growing

User Image essiepaul Posted - 20 hours ago

$AQST drops 0.12 in 30 effing min. who are the fukks trading this?? Has to be Armistice back and forth for their nickels

User Image RoyMunson69 Posted - 21 hours ago

$AQST Tampon dispensers been inactive lately. Good job. Means it might be time to buy soon

User Image drose0527 Posted - 22 hours ago

$AQST possible daily turnaround

User Image Swimmers Posted - 22 hours ago

$AQST looking good!

User Image TIG2 Posted - 22 hours ago

$AQST 32,480 on the bid at 4.74 will it get taken out ? Probably

User Image WaspofWallStreet Posted - 23 hours ago

@StockGPTchat $AQST a little over 15,000 shares at 3.17. thoughts on profit taking and Their future.

User Image gilmeriken Posted - 1 day ago

$AQST $ASPI $ZVRA This message looks familiar… https://stocktwits.com/bailees_imp/message/593311404

User Image Reed_Truong Posted - 1 day ago

$AQST $ZVRA $ASPI LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image Outrageous Posted - 1 day ago

$AQST Between Blackrock Finance and Blackrock Inc. it now looks collectively they own over 11M shares:

User Image Outrageous Posted - 1 day ago

$AQST Almost 60% institutional ownership:

User Image Outrageous Posted - 1 day ago

$AQST Today is day 2 of one on one meetings at the Jefferies London Annual Healthcare Conference: let’s go……….

User Image shaveapenny Posted - 1 day ago

$AQST unless the market tanks or RFK Jr goes rogue, I think $4.38 was the new bottom. The application for the NDA for 109, should be coming within the next 40 days. I trust Dan Barber and his team. Stay positive Team AQST!

Analyst Ratings
JMP Securities Market Outperform Sep 30, 24
Leerink Partners Outperform Sep 30, 24
HC Wainwright & Co. Buy Sep 30, 24
HC Wainwright & Co. Buy Aug 14, 24
JMP Securities Market Outperform Aug 12, 24
HC Wainwright & Co. Buy Jul 26, 24
JMP Securities Market Outperform Jun 26, 24
HC Wainwright & Co. Buy Jun 5, 24
Leerink Partners Outperform May 10, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Boyd Peter E. SVP-Bus. Process & I.. SVP-Bus. Process & Info. Tech. Jun 14 Buy 0.81 5,000 4,050 59,532 06/15/22
Barber Daniel Chief Executive Offi.. Chief Executive Officer Jun 08 Buy 0.96 91,743 88,073 193,702 06/10/22
Schobel Alexander Mark Chief Innovation/Tec.. Chief Innovation/Tech Officer Jun 08 Buy 0.96 45,871 44,036 882,871 06/10/22
Boyd Peter E. SVP-Bus. Process & I.. SVP-Bus. Process & Info. Tech. Jun 08 Buy 0.96 2,293 2,201 54,532 06/10/22
BRAENDER LORI J General Counsel General Counsel Jun 08 Buy 0.96 13,761 13,211 38,761 06/10/22
Schobel Alexander Mark Chief Innovation/Tec.. Chief Innovation/Tech Officer Feb 10 Sell 6.75 35,000 236,250 837,000 02/10/21